174 related articles for article (PubMed ID: 27815768)
1. Diabetes and kidney cancer outcomes: a propensity score analysis.
Nayan M; Finelli A; Jewett MA; Juurlink DN; Austin PC; Kulkarni GS; Hamilton RJ
Endocrine; 2017 Feb; 55(2):470-477. PubMed ID: 27815768
[TBL] [Abstract][Full Text] [Related]
2. Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis.
Nayan M; Finelli A; Jewett MA; Juurlink DN; Austin PC; Kulkarni GS; Hamilton RJ
Clin Genitourin Cancer; 2017 Apr; 15(2):300-305. PubMed ID: 27424258
[TBL] [Abstract][Full Text] [Related]
3. Statin use and kidney cancer outcomes: A propensity score analysis.
Nayan M; Finelli A; Jewett MAS; Juurlink DN; Austin PC; Kulkarni GS; Hamilton RJ
Urol Oncol; 2016 Nov; 34(11):487.e1-487.e6. PubMed ID: 27427224
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma.
Psutka SP; Stewart SB; Boorjian SA; Lohse CM; Tollefson MK; Cheville JC; Leibovich BC; Thompson RH
J Urol; 2014 Dec; 192(6):1620-7. PubMed ID: 24931804
[TBL] [Abstract][Full Text] [Related]
5. Oncological outcomes of minimally invasive partial versus minimally invasive radical nephrectomy for cT1-2/N0/M0 clear cell renal cell carcinoma: a propensity score-matched analysis.
Simone G; Tuderti G; Anceschi U; Papalia R; Ferriero M; Misuraca L; Minisola F; Mastroianni R; Costantini M; Guaglianone S; Sentinelli S; Gallucci M
World J Urol; 2017 May; 35(5):789-794. PubMed ID: 27578234
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis.
Nayan M; Jalali S; Kapoor A; Finelli A; So A; Rendon R; Breau RH; Lavallee LT; Tanguay S; Heng D; Kawakami J; Basappa NS; Bjarnason G; Pouliot F; Hamilton RJ
Urol Oncol; 2019 Sep; 37(9):576.e11-576.e16. PubMed ID: 31285115
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of diabetes mellitus in localized renal cell carcinoma.
Lee S; Hong SK; Kwak C; Kim HH; Lee SE
Jpn J Clin Oncol; 2012 Apr; 42(4):318-24. PubMed ID: 22389274
[TBL] [Abstract][Full Text] [Related]
8. Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis.
O'Malley RL; Hayn MH; Brewer KA; Underwood W; Hellenthal NJ; Kim HL; Sorokin I; Schwaab T
World J Urol; 2015 Nov; 33(11):1807-14. PubMed ID: 25805189
[TBL] [Abstract][Full Text] [Related]
9. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis.
Gershman B; Thompson RH; Moreira DM; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
J Urol; 2017 Mar; 197(3 Pt 1):574-579. PubMed ID: 27663461
[TBL] [Abstract][Full Text] [Related]
10. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach.
Badalato GM; Kates M; Wisnivesky JP; Choudhury AR; McKiernan JM
BJU Int; 2012 May; 109(10):1457-62. PubMed ID: 21933334
[TBL] [Abstract][Full Text] [Related]
11. Preserving Renal Function through Partial Nephrectomy Depends on Tumor Complexity in T1b Renal Tumors.
Yoo S; You D; Jeong IG; Hong B; Hong JH; Kim CS; Ahn H; Song C
J Korean Med Sci; 2017 Mar; 32(3):495-501. PubMed ID: 28145654
[TBL] [Abstract][Full Text] [Related]
12. Overall survival and development of stage IV chronic kidney disease in patients undergoing partial and radical nephrectomy for benign renal tumors.
Kaushik D; Kim SP; Childs MA; Lohse CM; Costello BA; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Eur Urol; 2013 Oct; 64(4):600-6. PubMed ID: 23280319
[TBL] [Abstract][Full Text] [Related]
13. Diabetes Mellitus as an Independent Predictor of Survival of Patients Surgically Treated for Renal Cell Carcinoma: A Propensity Score Matching Study.
Lee H; Kwak C; Kim HH; Byun SS; Lee SE; Hong SK
J Urol; 2015 Dec; 194(6):1554-60. PubMed ID: 26066406
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Trinh QD; Lee RK; Fajkovic H; Novara G; Margulis V; Lotan Y; Martinez-Salamanca JI; Matsumoto K; Seitz C; Remzi M; Karakiewicz PI; Scherr DS; Briganti A; Kautzky-Willer A; Bachmann A; Shariat SF;
Eur J Surg Oncol; 2014 Jan; 40(1):113-20. PubMed ID: 24113620
[TBL] [Abstract][Full Text] [Related]
15. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
17. Outcomes following partial nephrectomy by tumor size.
Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
[TBL] [Abstract][Full Text] [Related]
18. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy.
Viers BR; Houston Thompson R; Psutka SP; Lohse CM; Cheville JC; Leibovich BC; Tollefson MK; Boorjian SA
Urol Oncol; 2015 Sep; 33(9):388.e11-8. PubMed ID: 25700974
[TBL] [Abstract][Full Text] [Related]
19. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
20. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
